Illumina has urged a DC federal judge to send the Federal Trade Commission’s suit challenging the biotech firm’s planned US$8 billion takeover of Grail to California.
The Federal Trade Commission has filed a lawsuit to block Illumina’s $7.1 billion acquisition of Grail, a liquid biopsy specialist. If FTC is successful, San Diego, CA-based Illumina would fail to bring Grail, the company it launched in 2016, back into the fold.
FTC’s complaint alleges the proposed acquisition will diminish innovation in the U.S. market for multi-cancer early detection tests. MCED tests could be used to detect up to 50 types of cancer, most of which are not screened for at all today, saving millions of lives around the world.
Illumina said it intends to pursue all legal options to complete the acquisition and deliver the strategic benefits to its stakeholders.
“Combining Grail’s innovative multi-cancer early detection test with Illumina’s experience and scale will enable more patients in both the United States and worldwide to garner access to Grail’s test faster,” said Hans Bishop, CEO of Grail. “We continue to believe that together we could transform cancer care by catching more cancers earlier.”
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
FTC Chief Warns of Healthcare Price Fixing Risks Amid Tech Advancements
Apr 24, 2024 by
CPI
Amazon’s Investment in Anthropic Faces Antitrust Scrutiny
Apr 24, 2024 by
CPI
Italian Antitrust Authority Fines Amazon €10 Million for Unfair Trade Practices
Apr 24, 2024 by
CPI
Tuta Mail Raises Alarm Over Google Search Ranking Plunge Amidst DMA Rollout
Apr 24, 2024 by
CPI
UK Regulator Investigates Tech Giants’ AI Partnerships Amid Competition Concerns
Apr 24, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Economics of Criminal Antitrust
Apr 19, 2024 by
CPI
Navigating Economic Expert Work in Criminal Antitrust Litigation
Apr 19, 2024 by
CPI
The Increased Importance of Economics in Cartel Cases
Apr 19, 2024 by
CPI
A Law and Economics Analysis of the Antitrust Treatment of Physician Collective Price Agreements
Apr 19, 2024 by
CPI
Information Exchange In Criminal Antitrust Cases: How Economic Testimony Can Tip The Scales
Apr 19, 2024 by
CPI